Academic literature on the topic 'Primary pharmaceutical manufacturing'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Primary pharmaceutical manufacturing.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Primary pharmaceutical manufacturing"

1

Sarin, Subhash C., Hanif D. Sherali, and Lingrui Liao. "Primary pharmaceutical manufacturing scheduling problem." IIE Transactions 46, no. 12 (2014): 1298–314. http://dx.doi.org/10.1080/0740817x.2014.882529.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ouranidis, Andreas, Christina Davidopoulou, Reald-Konstantinos Tashi, and Kyriakos Kachrimanis. "Pharma 4.0 Continuous mRNA Drug Products Manufacturing." Pharmaceutics 13, no. 9 (2021): 1371. http://dx.doi.org/10.3390/pharmaceutics13091371.

Full text
Abstract:
Continuous mRNA drugs manufacturing is perceived to nurture flow processes featuring quality by design, controlled automation, real time validation, robustness, and reproducibility, pertaining to regulatory harmonization. However, the actual adaptation of the latter remains elusive, hence batch-to-continuous transition would a priori necessitate holistic process understanding. In addition, the cost related to experimental, pilot manufacturing lines development and operations thereof renders such venture prohibitive. Systems-based Pharmaceutics 4.0 digital design enabling tools, i.e., converging mass and energy balance simulations, Monte-Carlo machine learning iterations, and spatial arrangement analysis were recruited herein to overcome the aforementioned barriers. The primary objective of this work is to hierarchically design the related bioprocesses, embedded in scalable devices, compatible with continuous operation. Our secondary objective is to harvest the obtained technological data and conduct resource commitment analysis. We herein demonstrate for first time the feasibility of the continuous, end-to-end production of sterile mRNA formulated into lipid nanocarriers, defining the equipment specifications and the desired operational space. Moreover, we find that the cell lysis modules and the linearization enzymes ascend as the principal resource-intensive model factors, accounting for 40% and 42% of the equipment and raw material, respectively. We calculate MSPD 1.30–1.45 €, demonstrating low margin lifecycle fluctuation.
APA, Harvard, Vancouver, ISO, and other styles
3

Ngugi, Grace Wanjiru, and Esther Gitonga. "Generic Strategies and Performance of Pharmaceutical Manufacturing Companies in Nairobi County, Kenya." International Journal of Business Management, Entrepreneurship and Innovation 3, no. 1 (2021): 17–35. http://dx.doi.org/10.35942/jbmed.v3i1.157.

Full text
Abstract:
Pharmaceutical industry has been facing a lot of competition both from the inside and outside the country (importers of raw materials who also manufacture finished product). A report by the Kenya Pharmaceutical Sector Profile in 2018 indicated that imports have been rising sharply and grew by more than 30% between 2017 and 2018 in other sectors but a decline from the pharmaceutical manufacturing sector which could be attributed to the low-quality pharmaceutical products. The aim of this study was to analyze the generic strategies and performance of pharmaceutical manufacturing companies in Nairobi County, Kenya. The specific objectives were to: assess the effect of cost leadership strategy, differentiation strategy and focus strategy on performance of pharmaceutical companies in Nairobi County, Kenya. The study was informed by Porter’s Five Forces Model and Resource Based View theory. The study used descriptive research design. The population of this study was all the 22 pharmaceutical manufacturing companies in Nairobi County. The target population was the managers in the pharmaceutical manufacturing companies. The study was a census of all pharmaceutical manufacturing companies in Nairobi. A structured questionnaire was used for data collection. The questionnaire was pilot tested to determine its validity and reliability. The study used primary data which was gathered from the managers. Data collected was organized in spreadsheets for the purpose of analysis. It was coded and entered in Statistical Package for Social Sciences (SPSS, Version 22.0) for analysis. Correlation and regression analysis were conducted to find the relationship between the independent and dependent variables. The study found that cost leadership strategy, product differentiation strategy and focus strategy positively and significantly influenced performance of pharmaceutical companies in Nairobi County, Kenya. The study concluded that managing the production expenses enhances business performance because of increased profit value. Also, the study concluded that using technology to automate business operations lowers the cost thus increasing profitability. In addition to that, the study concluded that providing high quality products to customers builds customer loyalty which translates to improved performance. Similarly, the research concluded that lowering prices relative to that of competitors attracts more customers leading to increased sales volume. It was recommended that pharmaceutical firms should always aim at lowering the cost of production to reap optimal profits. However, these products should meet the quality demands in the market. It was also recommended that businesses should conduct customer satisfaction surveys to bridge the niche that may be identified. This way, businesses will be able to offer the relevant products and services and gain customer loyalty which eventually leads to increased profitability. In addition, it was recommended that non price competition strategies such as product packaging should be adopted by pharmaceutical firms to increase profitability. Customers would prefer to buy uniquely packaged products as they appear appealing. Future areas of study should focus on other competitive strategies since the three generic strategies that were identified did not account for 100% of the variation in performance of pharmaceutical firms.
APA, Harvard, Vancouver, ISO, and other styles
4

Prabhakar V S, Beula Evangeline C, Aravindhanathan V, Sruthi N, and Gowthamarajan K. "Regulatory Comparative Quality Systems of India and USA and its Significance in Pharmaceutical Industry Facilities." International Journal of Research in Pharmaceutical Sciences 11, SPL4 (2020): 2457–62. http://dx.doi.org/10.26452/ijrps.v11ispl4.4498.

Full text
Abstract:
The intentions of the current study are to compare the regulatory requirements of USFDA and CDSCO-Schedule M in GMP with significance to the pharmaceutical industry to speed up the criteria for enforcement to facilitate the regulatory approval of specified pharmaceutical products in the United States and India. The literature search is done using different resources, such as regulatory authority websites, pharmaceutical review articles, journals and public domains. To discuss the numerous dilemmas, root causes and challenges confront by pharmaceutical companies and to suggest remedial and pro-active measures to GMP issues and all pharmaceutical manufacturers are required to develop and enforce effective quality control systems in order to ensure quality. Whereas the regulated markets like the United States have well-established guidance compared to emerging markets like India on good manufacturing practice compliance, to assess the effectiveness of this quality management systems, inspections are carried out on manufacturing units. The primary objective of the analysis is to differentiate between the type of application or license that causes the inspection and the outcome of the inspection and to also provide enough details identified by the authority during the evaluation.
APA, Harvard, Vancouver, ISO, and other styles
5

Aziza, Farida. "Comparison Review of Two Regulatory Agencies Regulation: Therapeutic Goods Administration (TGA) and the European Medicine Agency (EMA) in Relation to Good Manufacturing Practice (GMP) Guideline." Majalah Farmaseutik 17, no. 2 (2021): 243. http://dx.doi.org/10.22146/farmaseutik.v17i2.60237.

Full text
Abstract:
There are some regulatory bodies in the world that impacting the pharmaceutical industry to operate and perform Good Manufacturing Practice (GMP) principles. These regulatory bodies exist to ensure that the pharmaceutical product and other human supporting products have a high standard of quality, safety, and efficacy from product registration to product distribution to the patient. This article reviews some aspects which is regulated by two of regulatory entities including Therapeutic Goods Administration (TGA) and European Medicines Agency (EMA) in relation with Good Manufacturing Practice (GMP) principles. The GMP principles which is structured by these regulatory agencies may be originally created by the agencies or influenced by other regulatory body concepts. The guidance can be a primary source or second reference for the pharmaceutical industry in impacting countries depending on the guideline’s legal status. It is noticeable that both regulatory bodies have some similar concepts to support GMP implementation and some differentt practices which may be considered by the pharmaceutical industry when it is aimed to market their product in the regulated countries.
APA, Harvard, Vancouver, ISO, and other styles
6

Elsafty, Ashraf, and Mohamed Osman. "The Impact of COVID-19 on the Efficiency of Packing Lines in Pharmaceutical Manufacturing Sites in Egypt." International Journal of Business and Management 16, no. 7 (2021): 57. http://dx.doi.org/10.5539/ijbm.v16n7p57.

Full text
Abstract:
Corona Virus Disease COVID-19 has significantly impacted the pharmaceutical manufacturing sector. Production Efficiency in pharmaceutical facilities is questionable to withstand the drastic conditions under which the drug manufacturing supply chains are. Overall Equipment Effectiveness (OEE) is a primary indicator of efficiency. The aim of this review is to demonstrate a comprehensive overview on the factors impacting OEE and how they are affected by COVID-19.
 
 This review was done on a multinational pharmaceutical manufacturing facility in Egypt. In order to better understand the business model under study and have clearer vision on the impact of COVID-19 on each aspect of it, the business anatomy model ‘9 Elements’ by Elsafty (2018) was used. The time horizon of this study is 2020 to understand the impact of the COVID-19 pandemic on the pharmaceutical manufacturing performance.
 
 The pandemic led to increase the pharmaceutical products demand which subsequently put a pressure on supply planners to alter the production scheduling. COVID-19 unraveled the weaknesses in the supply chains and the overreliance on materials suppliers of one source. This had a direct impact on the supply of materials and spare parts. Production efficiency has also been impacted by the health conditions of workers and operators might been community infected. Lack of high-skilled workers leads to decrease in the productivity due to the inability to manage and solve problems the right way and independently. Materials and finished goods quality are questionable in such situation. Introduction of counterfeit and falsified materials is a predictable side effect.
 
 It is concluded that OEE is affected by COVID-19 that moderates the inputs of OEE; availability, performance and quality. The pandemic has an impact (positive or negative) on the top losses of a machine efficiency.
APA, Harvard, Vancouver, ISO, and other styles
7

Latysheva, E. A., T. V. Latysheva, and I. A. Martynova. "Evaluation of efficacy and safety of intravenous immunoglobulin IG VENA in patients with primary antibody synthesis immunodeficiency." Russian Journal of Allergy 13, no. 1 (2016): 16–22. http://dx.doi.org/10.36691/rja364.

Full text
Abstract:
Replacement immunotherapy with intravenous immunoglobulin (IVIG) has been used successfully for the treatment of primary immunodeficiency (PID) for over 60 years. During this time, a huge step forward in purification and manufacturing methods has been made. In addition IVIG therapy has been approved for other diseases and this number is steadily expanding causing an appearance of new IVIG on the pharmaceutical market. These drugs vary in composition, manufacturing technology and, as a consequence, in safety, administration rate, and efficacy. The new IVIG on the Russian market IG Vena was recently introduced. It has already proved its safety and efficacy abroad. This article presents the experience of using the drug IG Vena in adults with PID in immunopathology department of the Institute of Immunology FMBA Russia.
APA, Harvard, Vancouver, ISO, and other styles
8

Bano, Gabriele, Riccardo De-Luca, Emanuele Tomba, Agnese Marcelli, Fabrizio Bezzo, and Massimiliano Barolo. "Primary Drying Optimization in Pharmaceutical Freeze-Drying: A Multivial Stochastic Modeling Framework." Industrial & Engineering Chemistry Research 59, no. 11 (2020): 5056–71. http://dx.doi.org/10.1021/acs.iecr.9b06402.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Shim, Hyunjin, and Hongkee Sah. "Qualification of Non-Halogenated Organic Solvents Applied to Microsphere Manufacturing Process." Pharmaceutics 12, no. 5 (2020): 425. http://dx.doi.org/10.3390/pharmaceutics12050425.

Full text
Abstract:
As a non-halogenated dispersed solvent, ethyl acetate has been most commonly used for the manufacturing of poly-d,l-lactide-co-glycolide (PLGA) microspheres. However, ethyl acetate-based microencapsulation processes face several limitations. This study was aimed at proposing ethyl formate as an alternative. Evaluated in this study was the solvent qualification of ethyl formate and ethyl acetate for microencapsulation of a hydrophobic drug into PLGA microspheres. An oil-in-water emulsion solvent extraction technique was developed to load progesterone into PLGA microspheres. Briefly, right after emulsion droplets were temporarily stabilized, they were subject to primary solvent extraction. Appearing semisolid, embryonic microspheres were completely hardened through subsequent secondary solvent extraction. Changes in process parameters of the preparative technique made it possible to manipulate the properties of emulsion droplets, progesterone behavior, and microsphere quality. Despite the two solvents showing comparable Hansen solubility parameter distances toward PLGA, ethyl formate surpassed ethyl acetate in relation to volatility and water miscibility. These features served as advantages in the microsphere manufacturing process, helping produce PLGA microspheres with better quality in terms of drug crystallization, drug encapsulation efficiency, microsphere size homogeneity, and residual solvent content. The present ethyl formate-based preparative technique could be an attractive method of choice for the production of drug-loaded PLGA microspheres.
APA, Harvard, Vancouver, ISO, and other styles
10

Oluwadare, Oreofe Praise, Omoniyi Joseph Ola-Olorun, and Billy Adegbola Oluwale. "Assessment of Total Quality Management Adoption Level in Pharmaceutical Manufacturing Companies in Southwestern Nigeria." International Journal of Engineering Research in Africa 43 (June 2019): 168–77. http://dx.doi.org/10.4028/www.scientific.net/jera.43.168.

Full text
Abstract:
The objective of this study was to assess the adoption level of Total Quality Management (TQM) in pharmaceutical manufacturing industry in Southwestern Nigeria by a cross-sectional survey of staff in Lagos, Ogun and Oyo States of Nigeria involving 348 of the 2,649 members, selected by multi-stage sampling. Primary data were collected using a set of pre-tested semi-structured questionnaire which sought to elicit information on the level of TQM adoption and designed with items on a Likert–type scale of seven alternative responses with weighting scores of 0 through 6, representing seven stages (levels) in the adoption process. Adoption was taken as becoming effective from the sixth stage (level 5). Factors influencing TQM adoption were identified by employing a Likert-type influence scale with five alternative responses and weighting scores of 0 - 4. Weighted averages (WA) and means of weighted averages (MWA) were employed in summarising the data while t-test and regression analyses were used in identifying significant relationships between variables at 5% significance level. The results showed that TQM adoption was at implementation (trial) level (MWA ≈ 4) and had not become actualised in the industry (t = 11.906, df = 3, p = .000). The study concluded that the adoption level of TQM in this industry was at trial level and TQM adoption was ineffective. Thus, there is need for improved adoption of the various components of TQM, particularly ‘leadership commitment’ and this can be achieved through sustained TQM training and advocacy by professional associations within the industry such as Nigerian Association of Industrial Pharmacists (NAIP) and Pharmaceutical Society of Nigeria (PSN).
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Primary pharmaceutical manufacturing"

1

Yao, Liming. "Modeling, Analysis and Solution Approaches for Some Optimization Problems: High Multiplicity Asymmetric Traveling Salesman, Primary Pharmaceutical Manufacturing Scheduling, and Lot Streaming in an Assembly System." Diss., Virginia Tech, 2008. http://hdl.handle.net/10919/27961.

Full text
Abstract:
This dissertation is devoted to the modeling, analysis and development of solution approaches for some optimization-related problems encountered in industrial and manufacturing settings. We begin by introducing a special type of traveling salesman problem called "High Multiplicity Asymmetric Traveling Salesman Problem" (HMATSP). We propose a new formulation for this problem, which embraces a flow-based subtour elimination structure, and establish its validity for this problem. The model is, then, incorporated as a substructure in our formulation for a lot-sizing problem involving parallel machines and sequence-dependent setup costs, also known as the "Chesapeake Problem". Computational results are presented to demonstrate the efficacy of our modeling approach for both the generic HMATSP and its application within the context of the Chesapeake Problem. Next, we investigate an integrated lot-sizing and scheduling problem that is encountered in the primary manufacturing facility of pharmaceutical manufacturing. This problem entails determination of production lot sizes of multiple products and sequence in which to process the products on machines, which can process lots (batches) of a fixed size (due to limited capacity of containers) in the presence of sequence-dependent setup times/costs. We approach this problem via a two-stage optimization procedure. The lot-sizing decision is considered at stage 1 followed by the sequencing of production lots at stage 2. Our aim for the stage 1 problem is to allocate batches of products to time-periods in order to minimize the sum of the inventory and backordering costs subject to the available capacity in each period. The consideration of batches of final products, in addition to those for intermediate products, which comprise a final product, further complicates the lot-sizing problem. The objective for the stage 2 problem is to minimize sequence-dependent setup costs. We present a novel unifying model and a column generation-based optimization approach for this class of lot-sizing and sequencing problems. Computational experience is first provided by using randomly generated data sets to test the performances of several variants of our proposed approach. The efficacy of the best of these variants is further demonstrated by applying it to the real-life data collected with the collaboration of a pharmaceutical manufacturing company. Then, we address a single-lot, lot streaming problem for a two-stage assembly system. This assembly system is different from the traditional flow shop configuration. It consists of m parallel subassembly machines at stage 1, each of which is devoted to the production of a component. A single assembly machine at stage 2, then, assembles products after components (one each from the subassembly machines at the first stage) have been completed. Lot-detached setups are encountered on the machines at the first and second stages. Given a fixed number of transfer batches (or sublots) from each of the subassembly machines at stage 1 to the assembly machine at stage 2, our problem is to find sublot sizes so as to minimize the makespan. We develop optimality conditions to determine sublot sizes for the general problem, and present polynomial-time algorithms to determine optimal sublot sizes for the assembly system with two and three subassembly machines at stage 1. Finally, we extend the above single-lot, lot streaming problem for the two-stage assembly system to multiple lots, but still, for the objective of minimizing the makespan. Due to the presence of multiple lots, we need to address the issue of the sequencing of the lots along with lot-splitting, a fact which adds complexity to the problem. Some results derived for the single-lot version of this problem have successfully been generalized for this case. We develop a branch-and-bound-based methodology for this problem. It relies on effective lower bounds and dominance properties, which are also derived. Finally, we present results of computational experimentation to demonstrate the effectiveness of our branch-and-bound-based methodology. Because of the tightness of our upper and lower bounds, a vast majority of the problems can be solved to optimality at root node itself, while for others, the average gap between the upper and lower bounds computed at node zero is within 0.0001%. For a majority of these problems, our dominance properties, then, effectively truncate the branch-and-bound tree, and obtain optimal solution within 500 seconds.<br>Ph. D.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Primary pharmaceutical manufacturing"

1

Lloyd, Steven M., and Ronald W. Wizimirski. "Flexible Containment for Primary Manufacturing/Bulk Operations." In Containment in the Pharmaceutical Industry. CRC Press, 2020. http://dx.doi.org/10.1201/9780429074943-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Menezes, J. C., A. P. Ferreira, L. O. Rodrigues, L. P. Brás, and T. P. Alves. "Chemometrics Role within the PAT Context: Examples from Primary Pharmaceutical Manufacturing." In Comprehensive Chemometrics. Elsevier, 2009. http://dx.doi.org/10.1016/b978-044452701-1.00012-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

"„ , . large-scale production rate Scale-up ratio = — - n\ small-scale production rate Disperse system scale-up ratios may vary from 10 to 100 for laboratory to pilot-plant process translation and 10 to 200 for scaling from pilot-plant to commercial produc-tion. Actual production rates may vary considerably from expected production rates, since overall process efficiency is dependent on a wide range of factors. The process-ing of disperse systems, whether liquid-liquid or liquid-solid, is still relatively empiri-cal due to the substantial interfacial effects that predominate and control the relevant unit operations. Furthermore, unit operations may function in a rate-limiting manner as the scale of operation increases from the laboratory bench to the pilot plant to com-mercial production. Thus, although conventional wisdom suggests the necessity of scale-up studies, the appropriate approach is not necessarily initiated with miniaturized com-mercial processing systems [5]. The concept of scale-up has taken on a substantive regulatory aspect in more re-cent years with the issuance of Guidance 22-90 by the Food and Drug Administration's (FDA's) Office of Generic Drugs in September 1990 and the establishment of the Scale-Up and Post Approval Changes (SUPAC) Task Force by the FDA's Center for Drug Evaluation and Research. In May 1993, the American Association of Pharmaceutical Scientists, the Food and Drug Administration, and the United States Pharmacopeia cosponsored a workshop on the scale-up of liquid and semisolid disperse systems [6]. The primary finished product attribute to control during the scale-up of a disperse sys-tem, whether manufactured in identical, similar, or different equipment, is the degree of sameness of the finished product relative to previous lots. The consensus of the workshop committee was that four criteria be used to evaluate sameness: (1) adherence to raw material controls and specifications; (2) adherence to in-process controls; (3) adherence to finished product specifications; and (4) bioequivalence to previous lots. The aim of this chapter is to provide the formulator with an appreciation, on the one hand, of the complexity of the scale-up problem associated with disperse systems, and an awareness, on the other hand, that scale-up problems can be resolved, to a great extent, by drawing on the vast literature and experience of chemical engineering. In 1964, H. W. Fowler [7] initiated a series of progress reports in pharmaceutical engi-neering that appeared over time in the periodical Manufacturing Chemist. Fowler's ouevre was distinguished by his focus on fundamentals, i.e., on material properties and on operation and process mechanisms. His intention was "to look at the literature of chemical engineering and to discuss developments which are relevant to pharmacy." It is the present author's intention (in part, through this chapter on scale-up of disperse systems) to validate the interdisciplinary process that Fowler began more than 30 years." In Pharmaceutical Dosage Forms. CRC Press, 1998. http://dx.doi.org/10.1201/9781420000955-60.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Primary pharmaceutical manufacturing"

1

Farrell, Paul, and Philip R. LeGoy. "Using Plasma Pyrolysis Vitrification (PPV) to Enhance Incineration Waste Ash Reduction in Ireland." In 10th Annual North American Waste-to-Energy Conference. ASMEDC, 2002. http://dx.doi.org/10.1115/nawtec10-1028.

Full text
Abstract:
Ireland has been called the Silicon Valley of Europe. Like the Silicon Valley in the U.S. it has a large amount of waste created by the Microchip Industry. Ireland is also an agricultural country. A large amount of bio-waste has been stockpiled in Ireland. This is the result of recent outbreaks/epidemics of animal diseases in the EU. The current growth industry of Ireland is the chemical and pharmaceutical manufacturing industry. Nine of the top ten pharmaceutical companies are manufacturing in Ireland. Wastes from these industries are often toxic and hazardous. They can contain large amounts of combustible organic compounds depending on their source. Since Ireland is an island it has special problems disposing of waste. Waste comes in as products as packaging and it doesn’t go out. The emerging solution is Incineration. Municipal Solid Waste (MSW) can contain many forms of metal and chemistry under normal conditions. When a large amount of the primary industry of a region is chemistry based and agricultural based there is the probability of more than usual amount of toxic residue in the refuse. The ash from incineration contains items such as dioxins &amp; heavy metals that are environmental toxins. Using a Plasma Pyrolysis Vitrification (PPV) process the volume of the resultant ash from incineration can be further reduced by as much as 30 to 1. A PPV process has an added advantage of giving an incineration facility the capability of rendering ash safe for reuse as construction material and as a side benefit reclaiming many valuable elemental components of the ash. The PPV plant can be used to destroy waste directly and economically as long as the gate fees are high. One byproduct of incinerator ash smelting/destruction using a PPV process is CO gas, a combustible fuel resource for power generation. Precious metals may also be reclaimed as an alloy material by-product.
APA, Harvard, Vancouver, ISO, and other styles
2

Schoenitz, Martin, Annika Hohlen, Wolfgang Augustin, and Stephan Scholl. "In-Process Cleaning of a Micro Heat Exchanger With Ultrasound During the Continuous Crystallization of Solid Lipid Nanoparticles." In ASME 2014 12th International Conference on Nanochannels, Microchannels, and Minichannels collocated with the ASME 2014 4th Joint US-European Fluids Engineering Division Summer Meeting. American Society of Mechanical Engineers, 2014. http://dx.doi.org/10.1115/icnmm2014-21821.

Full text
Abstract:
Process intensification by the application of microscale process engineering in reaction and heat transfer processes provides the opportunity of moving from batch to continuous manufacturing, mainly due to enhanced heat and mass transfer. These effects are primarily caused by the very high surface to volume ratio in microstructured devices. Further advantages, particularly suitable for sensitive products, are the low shear stress in the typically occurring laminar regime and the short residence time. The crystallization of drug carrying lipid nanoparticles (LNP) is a typical batch process for pharmaceutical products and is used here to demonstrate benefits, challenges and application possibilities of the conversion into a continuous microscale process. During the continuous crystallization of various LNP formulations in a micro-crystallizer, designed as a micro heat exchanger with square channels, several formulations led to fouling and blocking of small passages in the micro heat exchanger. To investigate the fouling behavior of different LNP formulations in detail, integral pressure drop measurements over the micro heat exchanger were performed. This contribution addresses the in-process cleaning of a micro heat exchanger for the continuous crystallization using ultrasound. Different ultrasound amplitudes and operation procedures were investigated. During processing the overall pressure drop was decreased significantly by induced ultrasound pulses. The investigations showed that in-process cleaning of a micro heat exchanger with ultrasound is possible for screening as well as for long term production of LNP. Also the product quality, given by the particle size and particle size distribution, is not affected by the ultrasound input.
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!